Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Privileged structures in GPCRs.

R P Bywater1

  • 1Magdalen College, OX1 4AU Oxford, England. robert.bywater@magd.ox.ac.uk

Ernst Schering Foundation Symposium Proceedings
|August 21, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comments on the paper "Levinthal's question revisited, and answered" by A. Ben-Naim.

Journal of biomolecular structure & dynamics·2013
Same author

Drug design for ever, from hype to hope.

Journal of computer-aided molecular design·2012
Same author

Modeling GPCRs.

Ernst Schering Foundation symposium proceedings·2007
Same author

Construction of the simplest model to explain complex receptor activation kinetics.

Journal of theoretical biology·2002
Same author

Dimerization of G-protein-coupled receptors.

Journal of medicinal chemistry·2001
Same author

Lipid-facing correlated mutations and dimerization in G-protein coupled receptors.

Protein engineering·2001

Privileged structures in drug design are recurring motifs that match conserved protein targets. These structures can be engineered to act as agonists or antagonists, aiding in drug discovery for various receptors.

Area of Science:

  • Medicinal Chemistry
  • Structural Biology
  • Pharmacology

Background:

  • Certain ligand substructures, termed 'privileged structures,' frequently appear in successful synthetic drugs.
  • These structures are hypothesized to match conserved structural motifs in diverse target proteins.

Purpose of the Study:

  • To explain the phenomenon of privileged structures in medicinal chemistry.
  • To explore their interaction with target proteins and potential in drug design.

Main Methods:

  • Analysis of recurring ligand substructures in pharmacologically active compounds.
  • Utilizing sequence-handling tools to predict receptor interactions.
  • Investigating binding site characteristics, particularly aromatic residue prevalence.

Related Experiment Videos

Main Results:

  • Privileged structures act as generic motifs binding to conserved protein structural elements.
  • They interact with receptor machinery controlling active/inactive states, enabling agonist/antagonist design.
  • Binding regions are rich in aromatic residues, explaining ligand composition.

Conclusions:

  • Privileged structures offer a rational approach to drug design by targeting conserved protein motifs.
  • This strategy can be applied to develop drugs for orphan receptors with unknown functions.